Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019.
Li Y, Harrison LJ, Chew KW, Currier JS, Wohl DA, Daar ES, Evering TH, Wu R, Giganti M, Ritz J, Javan AC, Coombs RW, Moser C, Hughes MD, Eron JJ, Smith DM, Li JZ. Li Y, et al. Among authors: wohl da. Clin Infect Dis. 2023 Feb 18;76(4):734-737. doi: 10.1093/cid/ciac818. Clin Infect Dis. 2023. PMID: 36210483 Free PMC article. Clinical Trial.
Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.
Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, Shikuma C, Mulligan K, Dube M, Wininger D, Huang J, Revuelta M, Currier J, Swindells S, Fichtenbaum C, Basar M, Tungsiripat M, Meyer W, Weihe J, Wanke C. Wohl DA, et al. Clin Infect Dis. 2006 Sep 1;43(5):645-53. doi: 10.1086/507333. Epub 2006 Jul 27. Clin Infect Dis. 2006. PMID: 16886161 Review.
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Xu X, Sklar P; SWITCHMRK 1 and 2 investigators. Eron JJ, et al. Lancet. 2010 Jan 30;375(9712):396-407. doi: 10.1016/S0140-6736(09)62041-9. Epub 2010 Jan 12. Lancet. 2010. PMID: 20074791 Clinical Trial.
Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study.
Wohl DA, Dumond JB, Blevins S, Pittard D, Ragan D, Wang R, Massengale K, Walsh K, Floris-Moore M, Eron JJ Jr, Richardson A, Hudgens MG, Kashuba AD. Wohl DA, et al. Antimicrob Agents Chemother. 2013 Feb;57(2):784-8. doi: 10.1128/AAC.01826-12. Epub 2012 Nov 26. Antimicrob Agents Chemother. 2013. PMID: 23183440 Free PMC article. Clinical Trial.
Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003-2009.
Zhu H, Napravnik S, Eron JJ, Cole SR, Ma Y, Wohl DA, Dou Z, Zhang Y, Liu Z, Zhao D, Yu L, Liu X, Cohen MS, Zhang F. Zhu H, et al. Among authors: wohl da. J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e150-7. doi: 10.1097/QAI.0b013e3182948d82. J Acquir Immune Defic Syndr. 2013. PMID: 23572014 Free PMC article.
265 results